Incentives for smoking cessation.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
17 07 2019
Historique:
pubmed: 18 7 2019
medline: 29 9 2019
entrez: 18 7 2019
Statut: epublish

Résumé

Financial incentives, monetary or vouchers, are widely used in an attempt to precipitate, reinforce and sustain behaviour change, including smoking cessation. They have been used in workplaces, in clinics and hospitals, and within community programmes. To determine the long-term effect of incentives and contingency management programmes for smoking cessation. For this update, we searched the Cochrane Tobacco Addiction Group Specialised Register, clinicaltrials.gov, and the International Clinical Trials Registry Platform (ICTRP). The most recent searches were conducted in July 2018. We considered only randomised controlled trials, allocating individuals, workplaces, groups within workplaces, or communities to smoking cessation incentive schemes or control conditions. We included studies in a mixed-population setting (e.g. community, work-, clinic- or institution-based), and also studies in pregnant smokers. We used standard Cochrane methods. The primary outcome measure in the mixed-population studies was abstinence from smoking at longest follow-up (at least six months from the start of the intervention). In the trials of pregnant women we used abstinence measured at the longest follow-up, and at least to the end of the pregnancy. Where available, we pooled outcome data using a Mantel-Haenzel random-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs), using adjusted estimates for cluster-randomised trials. We analysed studies carried out in mixed populations separately from those carried out in pregnant populations. Thirty-three mixed-population studies met our inclusion criteria, covering more than 21,600 participants; 16 of these are new to this version of the review. Studies were set in varying locations, including community settings, clinics or health centres, workplaces, and outpatient drug clinics. We judged eight studies to be at low risk of bias, and 10 to be at high risk of bias, with the rest at unclear risk. Twenty-four of the trials were run in the USA, two in Thailand and one in the Phillipines. The rest were European. Incentives offered included cash payments or vouchers for goods and groceries, offered directly or collected and redeemable online. The pooled RR for quitting with incentives at longest follow-up (six months or more) compared with controls was 1.49 (95% CI 1.28 to 1.73; 31 RCTs, adjusted N = 20,097; I Overall there is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up in mixed population studies. The effectiveness of incentives appears to be sustained even when the last follow-up occurs after the withdrawal of incentives. There is also moderate-certainty evidence, limited by some concerns about risks of bias, that incentive schemes conducted among pregnant smokers improve smoking cessation rates, both at the end of pregnancy and post-partum. Current and future research might explore more precisely differences between trials offering low or high cash incentives and self-incentives (deposits), within a variety of smoking populations.

Sections du résumé

BACKGROUND
Financial incentives, monetary or vouchers, are widely used in an attempt to precipitate, reinforce and sustain behaviour change, including smoking cessation. They have been used in workplaces, in clinics and hospitals, and within community programmes.
OBJECTIVES
To determine the long-term effect of incentives and contingency management programmes for smoking cessation.
SEARCH METHODS
For this update, we searched the Cochrane Tobacco Addiction Group Specialised Register, clinicaltrials.gov, and the International Clinical Trials Registry Platform (ICTRP). The most recent searches were conducted in July 2018.
SELECTION CRITERIA
We considered only randomised controlled trials, allocating individuals, workplaces, groups within workplaces, or communities to smoking cessation incentive schemes or control conditions. We included studies in a mixed-population setting (e.g. community, work-, clinic- or institution-based), and also studies in pregnant smokers.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methods. The primary outcome measure in the mixed-population studies was abstinence from smoking at longest follow-up (at least six months from the start of the intervention). In the trials of pregnant women we used abstinence measured at the longest follow-up, and at least to the end of the pregnancy. Where available, we pooled outcome data using a Mantel-Haenzel random-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs), using adjusted estimates for cluster-randomised trials. We analysed studies carried out in mixed populations separately from those carried out in pregnant populations.
MAIN RESULTS
Thirty-three mixed-population studies met our inclusion criteria, covering more than 21,600 participants; 16 of these are new to this version of the review. Studies were set in varying locations, including community settings, clinics or health centres, workplaces, and outpatient drug clinics. We judged eight studies to be at low risk of bias, and 10 to be at high risk of bias, with the rest at unclear risk. Twenty-four of the trials were run in the USA, two in Thailand and one in the Phillipines. The rest were European. Incentives offered included cash payments or vouchers for goods and groceries, offered directly or collected and redeemable online. The pooled RR for quitting with incentives at longest follow-up (six months or more) compared with controls was 1.49 (95% CI 1.28 to 1.73; 31 RCTs, adjusted N = 20,097; I
AUTHORS' CONCLUSIONS
Overall there is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up in mixed population studies. The effectiveness of incentives appears to be sustained even when the last follow-up occurs after the withdrawal of incentives. There is also moderate-certainty evidence, limited by some concerns about risks of bias, that incentive schemes conducted among pregnant smokers improve smoking cessation rates, both at the end of pregnancy and post-partum. Current and future research might explore more precisely differences between trials offering low or high cash incentives and self-incentives (deposits), within a variety of smoking populations.

Identifiants

pubmed: 31313293
doi: 10.1002/14651858.CD004307.pub6
pmc: PMC6635501
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD004307

Subventions

Organisme : Department of Health
ID : SRP/16/114/20
Pays : United Kingdom

Commentaires et corrections

Type : UpdateOf

Références

Addiction. 2002 Oct;97(10):1317-28; discussion 1325
pubmed: 12359036
Contemp Clin Trials. 2015 Nov;45(Pt B):449-457
pubmed: 26362691
BMC Public Health. 2015 Jan 31;15:58
pubmed: 25636330
J Appl Behav Anal. 2008 Winter;41(4):629-33
pubmed: 19192867
Nicotine Tob Res. 2003 Apr;5(2):205-13
pubmed: 12745493
MMWR Morb Mortal Wkly Rep. 2002 Apr 12;51(14):300-3
pubmed: 12002168
Am J Health Promot. 2001 Sep-Oct;16(1):21-6, ii
pubmed: 11575052
Am J Health Promot. 1999 Jul-Aug;13(6):347-57
pubmed: 10557507
Lancet Public Health. 2018 Nov;3(11):e536-e544
pubmed: 30342875
J Health Econ. 2015 Sep;43:154-69
pubmed: 26302940
Am J Public Health. 1997 Jul;87(7):1201-4
pubmed: 9240113
Drug Alcohol Depend. 2011 Oct 1;118(1):23-30
pubmed: 21414733
Am J Public Health. 2015 Jun;105(6):1198-205
pubmed: 25393172
Drug Alcohol Depend. 2017 Nov 1;180:178-192
pubmed: 28910690
J Subst Abuse Treat. 2015 Aug;55:29-38
pubmed: 25805668
Health Psychol Rev. 2014;8(3):286-95
pubmed: 25053215
J Appl Behav Anal. 2010 Fall;43(3):357-67
pubmed: 21358898
Drug Alcohol Depend. 2009 Nov 1;105(1-2):56-62
pubmed: 19615830
Prev Med. 1991 Nov;20(6):774-84
pubmed: 1766948
Bull World Health Organ. 2011 Jul 1;89(7):496-503
pubmed: 21734763
Psychopharmacology (Berl). 2011 Sep;217(2):279-87
pubmed: 21475970
Am J Addict. 2007 Nov-Dec;16(6):468-74
pubmed: 18058412
Drug Alcohol Depend. 1991 Dec;29(1):47-62
pubmed: 1797517
J Consult Clin Psychol. 1991 Apr;59(2):318-24
pubmed: 2030194
Cochrane Database Syst Rev. 2017 Sep 12;9:CD004305
pubmed: 28898403
Am J Drug Alcohol Abuse. 2016 May;42(3):296-305
pubmed: 26484869
Matern Child Health J. 2015 Jun;19(6):1393-9
pubmed: 25427877
Am J Public Health. 1990 Feb;80(2):205-6
pubmed: 2297068
Head Neck. 2018 Jul;40(7):1534-1547
pubmed: 29542262
Nicotine Tob Res. 2012 Mar;14(3):351-60
pubmed: 22157229
J Subst Abuse Treat. 2017 Jan;72:72-79
pubmed: 27658756
Behav Res Ther. 1980;18(1):45-50
pubmed: 7369987
Prev Med. 1999 Dec;29(6 Pt 1):590-8
pubmed: 10600442
Addict Behav. 2002 Nov-Dec;27(6):887-910
pubmed: 12369474
Soc Sci Med. 2015 Mar;128:10-7
pubmed: 25569610
J Consult Clin Psychol. 2018 May;86(5):464-473
pubmed: 29389142
Psychopharmacology (Berl). 1995 May;119(2):193-204
pubmed: 7659767
BMC Pregnancy Childbirth. 2013 Mar 15;13:66
pubmed: 23497294
Contemp Clin Trials. 2016 Sep;50:157-65
pubmed: 27521811
N Engl J Med. 2018 Jun 14;378(24):2302-2310
pubmed: 29791259
Cochrane Database Syst Rev. 2015 May 18;(5):CD004307
pubmed: 25983287
Exp Clin Psychopharmacol. 2005 May;13(2):102-10
pubmed: 15943543
Nicotine Tob Res. 2007 Oct;9(10):1043-51
pubmed: 17943620
J Drug Educ. 1984;14(2):109-18
pubmed: 6536732
Prev Med. 2006 Aug;43(2):150-1; discussion 151-3
pubmed: 16675005
Drug Alcohol Depend. 2014 Jul 1;140:208-12
pubmed: 24793364
BMJ Open. 2014 Jul 18;4(7):e005524
pubmed: 25037645
Trials. 2012 Jul 20;13:113
pubmed: 22818493
J Occup Environ Med. 2012 May;54(5):610-4
pubmed: 22476113
J Subst Abuse Treat. 2005 Jun;28(4):305-12
pubmed: 15925264
Med Health R I. 2004 Jan;87(1):9-12
pubmed: 14989074
Drug Alcohol Depend. 2007 Oct 8;90(2-3):224-7
pubmed: 17475418
Nicotine Tob Res. 2017 Jun 01;19(6):694-702
pubmed: 28486708
Exp Clin Psychopharmacol. 2006 May;14(2):171-9
pubmed: 16756421
Am J Prev Med. 1990 Jul-Aug;6(4):200-7
pubmed: 2223167
Nicotine Tob Res. 2009 Jun;11(6):739-49
pubmed: 19443788
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):12-8
pubmed: 16434580
Tob Control. 2000;9 Suppl 3:III67-9
pubmed: 10982912
Am J Health Promot. 1991 Jan-Feb;5(3):192-9
pubmed: 10148668
Matern Child Health J. 2011 Feb;15(2):188-97
pubmed: 20091107
J Appl Behav Anal. 2015 Spring;48(1):25-37
pubmed: 25640764
N Engl J Med. 2009 Jul 23;361(4):331-3
pubmed: 19625714
Exp Clin Psychopharmacol. 2007 Apr;15(2):176-86
pubmed: 17469941
J Consult Clin Psychol. 2010 Feb;78(1):62-71
pubmed: 20099951
Health Educ Q. 1990 Spring;17(1):99-118
pubmed: 2318654
Soc Sci Med. 2012 Dec;75(12):2509-14
pubmed: 23102753
Gesundheitswesen. 2002 Aug-Sep;64(8-9):492-8
pubmed: 12221614
Contemp Clin Trials. 2012 Jan;33(1):197-205
pubmed: 22005174
Drug Alcohol Depend. 2004 Dec 7;76(3):247-59
pubmed: 15561476
Behav Res Ther. 1981;19(2):117-23
pubmed: 7271687
Psychopharmacology (Berl). 2005 Nov;182(4):508-15
pubmed: 16167142
Eur J Health Econ. 2018 Jun;19(5):697-708
pubmed: 28646249
Addiction. 2008 Jun;103(6):1009-18
pubmed: 18482424
Behav Modif. 2000 Apr;24(2):184-201
pubmed: 10804679
Am J Prev Med. 2017 Dec;53(6):754-763
pubmed: 29079405
J Occup Environ Med. 2007 Aug;49(8):821-8
pubmed: 17693778
Addict Behav. 2017 Mar;66:17-25
pubmed: 27863323
BMJ Open. 2016 Jul 26;6(7):e011669
pubmed: 27466239
Addict Behav. 1993 Jul-Aug;18(4):455-64
pubmed: 8213300
J Occup Environ Med. 2011 Jan;53(1):62-7
pubmed: 21187795
Am J Psychiatry. 2013 Jan;170(1):94-101
pubmed: 23138961
J Behav Med. 1988 Aug;11(4):407-21
pubmed: 3070047
J Clin Psychiatry. 2014 Apr;75(4):336-43
pubmed: 24345356
BMJ. 2015 Jan 27;350:h134
pubmed: 25627664
JAMA. 2014 Mar 5;311(9):909-10
pubmed: 24493405
Drug Alcohol Depend. 2014 Jan 1;134:391-395
pubmed: 24128381
Gesundheitswesen. 2003 Apr;65(4):250-4
pubmed: 12751008
Drug Alcohol Depend. 2007 Apr 17;88(1):79-82
pubmed: 17049754
Nicotine Tob Res. 2014 Nov;16(11):1436-45
pubmed: 24935755
Exp Clin Psychopharmacol. 2007 Jun;15(3):245-55
pubmed: 17563211
N Engl J Med. 2009 Feb 12;360(7):699-709
pubmed: 19213683
Addiction. 2012 Oct;107(10):1868-77
pubmed: 22716774
J Laryngol Otol. 2016 Mar;130(3):278-83
pubmed: 26878376
Prog Clin Biol Res. 1989;293:231-42
pubmed: 2498905
Addict Behav. 1985;10(4):345-9
pubmed: 4091067
Health Educ Res. 2015 Feb;30(1):121-33
pubmed: 24848555
J Consult Clin Psychol. 1995 Jun;63(3):460-8
pubmed: 7608359
Addiction. 2017 May;112(5):875-883
pubmed: 27923264
Am J Health Behav. 2014 Sep;38(5):668-80
pubmed: 24933136
J Appl Behav Anal. 1984 Winter;17(4):477-83
pubmed: 6526768
Cochrane Database Syst Rev. 2017 Feb 14;2:CD001055
pubmed: 28196405
Med Klin (Munich). 2006 Sep 15;101(9):711-7
pubmed: 16977395
BMJ. 2009 Apr 09;338:b1415
pubmed: 19359291
Exp Clin Psychopharmacol. 2007 Feb;15(1):58-66
pubmed: 17295585
Prev Med. 2012 Nov;55 Suppl:S24-32
pubmed: 22525802
J Appl Behav Anal. 2008 Winter;41(4):527-38
pubmed: 19192857
Am J Prev Med. 1988 Mar-Apr;4(2):83-6
pubmed: 3395495
Exp Clin Psychopharmacol. 2010 Feb;18(1):32-6
pubmed: 20158292
J Behav Med. 1988 Jun;11(3):267-77
pubmed: 3172194
J Appl Behav Anal. 2008 Winter;41(4):609-15
pubmed: 19192864
Exp Clin Psychopharmacol. 2011 Feb;19(1):20-30
pubmed: 21341920
Cochrane Database Syst Rev. 2019 Feb 20;2:CD013272
pubmed: 30784046
BMC Public Health. 2013 Apr 15;13:343
pubmed: 23587161
Cochrane Database Syst Rev. 2017 Nov 17;11:CD003289
pubmed: 29148565
Prev Med. 2006 Jan;42(1):33-9
pubmed: 16289314
Addict Behav. 2013 Apr;38(4):2084-8
pubmed: 23403276
Behav Res Ther. 1983;21(4):425-33
pubmed: 6626113
Drug Alcohol Depend. 2014 Jul 1;140:63-8
pubmed: 24768410
J Psychoactive Drugs. 2007 Dec;39(4):487-97
pubmed: 18303706
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004307
pubmed: 18646105
Am J Public Health. 2002 Feb;92(2):274-9
pubmed: 11818305
Nicotine Tob Res. 2013 Nov;15(11):1934-8
pubmed: 23645606
J Subst Abuse Treat. 2017 Jan;72:89-96
pubmed: 27542442
Prev Med. 2012 Nov;55 Suppl:S33-40
pubmed: 22227223
Exp Clin Psychopharmacol. 1999 May;7(2):174-81
pubmed: 10340157
Drug Alcohol Depend. 2009 Oct 1;104 Suppl 1:S100-5
pubmed: 19442460
BMC Public Health. 2012 Nov 27;12:1032
pubmed: 23181988
Exp Clin Psychopharmacol. 2014 Aug;22(4):348-55
pubmed: 24840638
Tob Control. 2014 Sep;23(5):428-33
pubmed: 23733918
Birth. 1984 Winter;11(4):217-24
pubmed: 6568824
J Occup Med. 1992 Aug;34(8):771-4
pubmed: 1506933
N Engl J Med. 2015 May 28;372(22):2108-17
pubmed: 25970009
Am J Prev Med. 2013 Nov;45(5):533-42
pubmed: 24139765
Addiction. 2010 Nov;105(11):2023-30
pubmed: 20840188
Nicotine Tob Res. 2004 Dec;6(6):1015-20
pubmed: 15801574
Drug Alcohol Depend. 2009 Oct 1;104(3):197-203
pubmed: 19570621
Psychol Rec. 2008 Spring;58(2):163-174
pubmed: 23825867
J Epidemiol Community Health. 2007 Aug;61(8):750; author reply 750-1
pubmed: 17630378
Addict Behav. 1987;12(2):181-4
pubmed: 3630804
BMC Pregnancy Childbirth. 2012 Apr 02;12:24
pubmed: 22471787
Addict Behav. 1989;14(2):121-8
pubmed: 2728951
PLoS One. 2014 Mar 11;9(3):e90347
pubmed: 24618584
Int J Behav Med. 2013 Mar;20(1):114-20
pubmed: 22094998
Am J Community Psychol. 1989 Dec;17(6):785-99
pubmed: 2636539
Addiction. 2016 Feb;111(2):360-70
pubmed: 26370095
Trials. 2012 Jun 21;13:88
pubmed: 22721577
BMC Public Health. 2016 Oct 6;16(1):1056
pubmed: 27716132
Exp Clin Psychopharmacol. 2010 Jun;18(3):221-8
pubmed: 20545386
Addiction. 2015 Apr;110(4):680-8
pubmed: 25727238
J Appl Behav Anal. 2008 Winter;41(4):481-97
pubmed: 19192854
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD008137
pubmed: 19821444
Exp Clin Psychopharmacol. 2006 Aug;14(3):306-10
pubmed: 16893273
J Subst Abuse Treat. 2017 Nov;82:55-66
pubmed: 29021116
Alcohol Clin Exp Res. 2002 Dec;26(12):1950-1
pubmed: 12500132
PLoS One. 2014 Oct 30;9(10):e111322
pubmed: 25357121
Public Health Rep. 1983 Sep-Oct;98(5):497-502
pubmed: 6414037
Psychopharmacology (Berl). 2005 Sep;181(3):486-95
pubmed: 16034556
Nicotine Tob Res. 2002 May;4(2):149-59
pubmed: 12028847
Clin Pharmacol Ther. 2010 Jul;88(1):109-14
pubmed: 20485335
Nicotine Tob Res. 2004 Apr;6 Suppl 2:S163-79
pubmed: 15203819
J Epidemiol Community Health. 2006 Sep;60(9):757-9
pubmed: 16905718
Psychiatr Serv. 2018 Mar 1;69(3):274-280
pubmed: 29137560
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004307
pubmed: 15846705
J Behav Med. 1990 Aug;13(4):403-18
pubmed: 2246786
Am J Health Promot. 1993 Nov-Dec;8(2):98-100
pubmed: 10146823
Am J Public Health. 1993 Mar;83(3):395-401
pubmed: 8438979
Gesundheitswesen. 2007 Jan;69(1):38-44
pubmed: 17347931
Nicotine Tob Res. 2010 May;12(5):483-8
pubmed: 20339141
JAMA. 1984 Feb 17;251(7):911-5
pubmed: 6363731
J Consult Clin Psychol. 2002 Feb;70(1):142-52
pubmed: 11860040
J Obstet Gynecol Neonatal Nurs. 2015 Mar-Apr;44(2):236-45
pubmed: 25656503
J Appl Behav Anal. 2008 Winter;41(4):617-22
pubmed: 19192865
Dtsch Med Wochenschr. 2002 Mar 1;127(9):430-6
pubmed: 11870557
Health Educ Res. 1997 Mar;12(1):129-38
pubmed: 10166900
BMJ Open. 2017 Sep 01;7(9):e017467
pubmed: 28864706
Prev Med. 2014 Nov;68:51-7
pubmed: 24704135
Am J Community Psychol. 1994 Apr;22(2):257-71
pubmed: 7977180
Addict Behav. 2009 Aug;34(8):705-8
pubmed: 19411145
J Community Health. 2016 Dec;41(6):1146-1152
pubmed: 27688221
Cochrane Database Syst Rev. 2011 Apr 13;(4):CD004307
pubmed: 21491388
Prev Med. 2000 Oct;31(4):299-307
pubmed: 11006054
Prev Med. 1990 Jul;19(4):414-23
pubmed: 2399223
Drug Alcohol Depend. 2006 Nov 8;85(2):138-41
pubmed: 16720082
BMC Public Health. 2014 Jul 28;14:761
pubmed: 25074396
Exp Clin Psychopharmacol. 2010 Feb;18(1):37-50
pubmed: 20158293
Nicotine Tob Res. 2018 Nov 15;20(12):1481-1488
pubmed: 29253215
Addict Behav. 2014 Mar;39(3):717-20
pubmed: 24321696
Am J Prev Med. 2010 Feb;38(2 Suppl):S263-74
pubmed: 20117611
Am J Health Promot. 1989 Spring;3(4):11-6
pubmed: 22206390
J Am Coll Cardiol. 2016 Aug 23;68(8):777-85
pubmed: 27539168
Am J Health Promot. 2012 Mar-Apr;26(4):204-7
pubmed: 22375568
Psychopharmacology (Berl). 2009 Aug;205(2):305-18
pubmed: 19390842
JAMA Intern Med. 2017 Dec 1;177(12):1798-1807
pubmed: 29084312
J Occup Health. 2006 May;48(3):175-82
pubmed: 16788278
BMJ. 2014 Apr 02;348:g2458
pubmed: 24696175
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH